Rituximab biosimilar - Prestige BioPharma
Alternative Names: PBP 1506; Rituxan biosimilar - Prestige BioPharmaLatest Information Update: 14 Jan 2022
At a glance
- Originator Prestige BioPharma
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Arthritis; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for research development in Arthritis in Singapore (Parenteral)
- 28 Feb 2021 No recent reports of development identified for research development in Non-Hodgkin's-lymphoma in Singapore (Parenteral)
- 18 Jan 2017 Early research in Arthritis in Singapore (Parenteral) before January 2017 (Prestige BioPharma pipeline, January 2017)